Dana Livne-Segev

Learn More
BACKGROUND The VEGFR/PDGFR inhibitor sunitinib was approved in Israel in 2008 for the treatment of metastatic renal cell carcinoma (mRCC), based on an international trial. However, the efficacy of sunitinib treatment in Israeli mRCC patients has not been previously reported. OBJECTIVES To report the outcome and associated factors of sunitinib treatment in(More)
  • 1